| Literature DB >> 35118029 |
Zhengyang Tao1, Jiao Wang2, Minjuan Zhu3, Zhihong Lin3, Jun Zhao4, Yu Tang3, Hongwei Deng5.
Abstract
Orthokeratology is currently known as one of the most effective methods of myopia control in the process of rapid deterioration of the global myopia prevalence. As orthokeratology is widely used, it is necessary to evaluate its complications reasonably and accurately. Eye surface problems in children, such as dry eyes, have received increasing attention. At present, there is no conclusive evidence on how orthokeratology affects the ocular surface, especially the tears. To our knowledge, this is the first study to explore the relationship between orthokeratology lenses and tears through meta-analysis. However, it is still challenging to get a convincing conclusion and a higher level of evidence in this meta-analysis. Reasons for this include limitation of study design, lack of clarity on important confounding factors, lack of appropriate statistical tools, and other biases. This paper will analyze the dilemma existing in the current research from different perspectives to provide meaningful information for future studies in this field.Entities:
Keywords: Newcastle-Ottawa scale; children; orthokeratology wearing; pediatric ophthalmology; tear quality changing
Year: 2022 PMID: 35118029 PMCID: PMC8804288 DOI: 10.3389/fped.2021.773484
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Figure 1Orthokeratologylenses with different designs and the layers of tears.
Figure 2The detailed literature screening process.
Characteristic of the included studies in the meta-analysis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Li et al. ( | Prospective, one-arm study | China | 2013.01–2013.08 | 12 (1,3,6,12) | 40 (80) | 22/18 | 13.68 ± 2.32 (11–18) | −3.61 ± 1.48 | 8–10 h | NA |
| 2 | Liu et al. ( | Cohort study | China | 2017.03–2018.05 | 12 (1,3,6,12) | 36 (72) | 15/21 | 13.52 ± 1.12 (12–18) | −2.94 ± 1.30 | 8–10 h | NA |
| 3 | Na et al. ( | Prospective, one-arm study | South Korea | NA (study period: 2010.01–2014.07) | 36 (6,12,24,36) | 58 (58) | 18/40 | NA (7–18) | −2.97 ± 2.02 | 8 h | NA |
| 4 | Shi et al. ( | Cohort study | China | 2013.10–2013.12 | 24 (3,6,24) | 26 (51) | 14/12 | 12.46 ± 2.19 (9–17) | NA | NA | NA |
| 5 | Wang et al. ( | Prospective, one-arm study | China | 2015.01–2015.07 | 24 (1,3,6,12,24) | 59 (59) | 27/32 | 12.03 ± 2.31 (7–18) | −3.70 ± 1.39 | 8 h | YES (by contacting the author) |
| 6 | Yan et al. ( | Prospective, one-arm study | China | 2013.1–2013.8 | 6 (1,6) | 59 (59) | 30/38 | NA (8–14) | NA | NA | NA |
| 7 | Yang et al. ( | Cohort study | China | 2018.01–2018.06 | 12 (1,3,6,12) | 60 (60) | 23/37 | 12.6 ± 2.5 (8–14) | −3.50 ± 0.80 | 8 h | YES |
| 8 | Yu-Ling et al. ( | Cohort study | China | 2016.01–2016.06 | 12 (12) | 36 (72) | 21/15 | 13.61 ± 2.41 (8–18) | −1.38 ± 0.23 | 8–10 h | YES (by contacting the author) |
| 9 | Zhang et al. ( | Prospective, one-arm study | China | 2017.01–2017.11 | 12 (1,3,6,12) | 55 (106) | 26/29 | 12.04 ± 2.51 (12–18) | NA | NA | NA |
| 10 | Zhao et al. ( | Randomized controlled trial | China | 2019.01–2020.08 | 12 (3,6,12) | 20 (40) | 10/10 | 11.00 ± 1.17 (8–14) | −2.75 ± 0.46 | 8 h | NA |
NA, not available; SE, spherical equivalent.
Quality evaluation of included studies using NOS.
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| Li et al. ( | ⋆ | NA | ⋆ | ⋆ | 0 | ⋆ | ⋆ | ⋆ | 6 |
| Liu et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | 8 |
| Na et al. ( | ⋆ | NA | ⋆ | ⋆ | 0 | ⋆ | ⋆ | 0 | 5 |
| Shi et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | 0 | ⋆ | ⋆ | ⋆ | 7 |
| Wang et al. ( | ⋆ | NA | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | ⋆ | 8 |
| Yan et al. ( | ⋆ | NA | ⋆ | ⋆ | 0 | ⋆ | ⋆ | ⋆ | 6 |
| Yang et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | ⋆ | ⋆ | 9 |
| Yu-Ling et al. ( | ⋆ | ⋆ | ⋆ | ⋆ | ⋆⋆ | ⋆ | ⋆ | ⋆ | 9 |
| Zhang et al. ( | ⋆ | NA | ⋆ | ⋆ | 0 | ⋆ | ⋆ | ⋆ | 6 |
NOS, Newcastle-Ottawa quality assessment score.
⋆The star indicates a score of 1, and ⋆⋆ indicates a score of 2.
A follow-up period of equal to or more than 3 months was considered as “follow-up long enough for outcomes to occur”.
A star is allocated when the cohort has a loss of follow up rate of <10%.
Scoring scale for “Comparability” column in Newcastle-Ottawa Scale.
|
|
|
|
|
|---|---|---|---|
| √ | √ | √ | ⋆⋆ |
| √ | × | √ | ⋆ |
| √ | √ | × | ⋆ |
| √ | × | × | 0 |
| × | √ | √ | × |
| × | × | √ | 0 |
| × | √ | × | 0 |
| × | × | × | 0 |
“√” refers to “Yes”, and “ × ” refers to “No”.
⋆The star indicates a score of 1, and ⋆⋆indicates a score of 2.
When a study gets three and two “√” in the .
The 1.
The 2.
Modified Jadad Score for < Clinical efficacy of 0.01% atropine in retarding the progression of myopia in children>.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
| Randomization | Not randomized or inappropriate method of randomization | The study was described as randomized | The method of randomization was described and it was appropriate | 1 |
| Concealment of allocation | Not describe the method of allocation concealment | The study was described as using allocation concealment method | The method of allocation concealment was described appropriately | 0 |
| Double blinding | Not blind or inappropriate method of blinding | The study was described as double blind | The method of double blinding was described and it was appropriate | 0 |
| Withdrawals and dropouts | Not describe the follow-up | A description of withdrawals and dropouts | 1 | |
| Total | 2 | |||
Figure 3The forest plots of tear break-up time changing after one to 6 months of orthokeratology wearing.
Figure 4The forest plots of the Schirmer I test and Ocular Surface Disease Index changing after 6 months of orthokeratology wearing.